Uniting biological toolkits for a new approach to ALS
DeepMind Blog · 2026-05-16
DeepMind's Co-Scientist bridged disciplinary gaps between MIT bioengineer Ritu Raman and Boston Children's Hospital chemical biologist Ryan Flynn, enabling a new collaborative research direction targeting RNA-based mechanisms and drugs for ALS treatment.
Appears in
Extraction
Topics: co-scientistalsrna-therapeuticsinterdisciplinary-researchai-for-science
Claims
- Co-Scientist compressed months of ALS literature review into rapid, targeted analysis aligned with Raman's tissue model capabilities.
- Co-Scientist's best leads for ALS involved RNA surface interactions, a domain outside Raman's tissue engineering expertise.
- The gap between Raman's and Flynn's expertise, surfaced by Co-Scientist, catalyzed a new interdisciplinary collaboration between the two labs.
- The combined team is now pursuing novel RNA-based mechanisms and RNA-based drugs as potential ALS therapies.
Key quotes
Co-Scientist compressed that work, quickly helping Raman interrogate the evidence in relation to her tissue model, turn ideas into testable hypotheses, and rank potential directions in accordance with the trade-offs labs actually face, such as feasibility and potential risk–reward.
That gap became the catalyst for collaboration.
Their hunt is now on for novel RNA-based mechanisms—and potentially RNA-based drugs—that could be used to target ALS.